Short Courses

Lieven Annemans is Professor of Health Economics at the Medical Faculty of Ghent University, Belgium. He is also Associate Partner of the consultancy company Vintura. He has 20 years of experience in health economic research in more than 20 countries and has published over 300 publications on health economic evaluations for medicines, devices, and diagnostics. Lieven was advisor to the Belgian Minister of Health from 2001 to 2003, President of the Flemish Health Council from 2003 to 2009, and President of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) from 2004-2005. He has also authored books on health economic evaluations (health economics for non-economists) and on the future of health care systems. He provides international lectures, trainings, and advice on health economics, health care systems, and health technology assessment (HTA).

Linus Jönsson is the Vice President of Medical Outcomes Research at H. Lundbeck A/S in Valby, Denmark and an affiliated researcher at the Karolinska Institute in Stockholm, Sweden. Dr. Jönsson earned his MD at Uppsala University in 2000, his MSc in Economics and Business Administration at the Stockholm School of Economics in 2001, and his PhD in Health Economics at the Karolinska Institute in 2003. He obtained a Swedish Medical License in 2004. Dr. Jönsson co-founded European Health Economics, an international consultancy in health economics and outcomes research, which was acquired by UnitedHealth Group in 2007. Following the acquisition, He managed the European operations of the company (now renamed Optum) prior to joining H. Lundbeck in May 2014. Dr. Jönsson is a member of the EFPIA task force on Health Technology Assessment and his research interests include economic evaluation of innovative therapies with specific focus on central nervous system disorders. He has authored approximately 80 peer-reviewed journal articles and textbook chapters.

Dr. Bradley Martin is currently Professor and was the founding head of the Pharmaceutical Evaluation and Policy (PEP) Division at the University of Arkansas for Medical Sciences College of Pharmacy. The Pharmaceutical Evaluation and Policy Division offers graduate and professional instruction and conducts research in pharmacoeconomics, patient reported outcomes, pharmaceutical economics, and large health claims data base analysis. Dr. Martin received his PharmD from the University of Illinois and earned his PhD in Pharmacy Care Administration from the University of Georgia. Dr. Martin’s research efforts have focused on conducting retrospective observational comparative effectiveness and economic analyses using large administrative data sets and national health surveys.  He conducts policy analyses, and develops cost effectiveness models and has contributed to the understanding of the opioid epidemic. Dr. Martin has over 90 peer-reviewed manuscripts published, which have been collectively cited over 4000 times, and his work has been funded by NIH, AHRQ, VA, and a variety of research foundations as well as partnerships with the pharmaceutical industry. Dr. Martin is contributing to national policy research on opioids and health care financing and has recently lead an international effort to improve the conduct and reporting of CER observational research organized by three national associations:  ISPOR, NPC, AMCP. 

Kevin Weinfurt, PhD, is Professor and Vice Chair for Research in the Department of Population Health Sciences at Duke University School of Medicine, where he is a member of the Duke Center for Health Measurement. He is also a Professor of Psychology and Neuroscience and a member of the Duke Clinical Research Institute. Dr. Weinfurt received his PhD in psychology from Georgetown University and did graduate work in the history of science and the philosophy of mind at Linacre College, Oxford University. Dr. Weinfurt conducts research on measuring patient-reported outcomes, medical decision making, and bioethics. Dr. Weinfurt was a Principal Investigator in the NIH PROMIS Network, where he led the development of the SexFS to measure male and female sexual function and satisfaction. He currently serves as the President of the PROMIS Health Organization and on the Board of Directors of the Society for Quality of Life Research. Dr. Weinfurt co-Chairs of the coordinating center for the NIH Health Systems Research Collaboratory and co-Chairs NIDDK’s Symptoms of Lower Urinary Tract Dysfunction Research Network. Dr. Weinfurt has led the analysis of PROs in multiple clinical trials, including the HF-ACTION trial (2008, JAMA), as well as other analyses of PRO endpoints in the context of trials. As an educator, Dr. Weinfurt co-Directs Duke University’s Masters-level Clinical Research Training Program and has taught undergraduate courses in introductory psychology, judgment and decision making, the psychology of medical decision making; and a graduate course in multivariate statistics. Dr. Weinfurt teaches a semester-long course on PROs for post-graduate level health professionals (mostly MDs). Dr. Weinfurt has been a lecturer on PROs for the NIH’s Introduction to the Principles and Practice of Clinical Research Course, which is delivered online to over 6,000 global students annually. Dr. Weinfurt has also taught and consulted for the FDA, served on several FDA advisory panels, and has conducted focus groups of FDA biostatisticians to understand their training needs regarding PROs.

Dr. Neil Hawkins is a Professor of Health Technology Assessment (HTA) at the University of Glasgow.  He was previously Vice President leading the global Health Economics practice at ICON PLC following its acquisition of Oxford Outcomes Ltd, where he served as a Member of the Board of Directors. Over the previous fifteen years, Neil has participated in methodological and applied research regarding the relative and cost-effectiveness of health technologies. In addition to participating individual evaluations, he has published articles discussing methods for network meta-analysis, cost-effectiveness modeling, value based pricing and the placebo effect. More recently, he has focused on the application of HTA “thinking” during the process of technology development and the development of conceptual models of value. He received Master’s Degrees in Health Economics (York) and Applied Statistics (Sheffield Hallam) and a BSc and PhD in Pharmacology (University of Bristol) and an MBA (University of Oxford).  He is also a Chartered Statistician with the Royal Statistical Society, UK. For more details please see: https://neilhawkins.wordpress.com/

Mark S. Roberts, MD, MPP is Professor and Chair of the Department of Health Policy and Management at the University of Pittsburgh Graduate School of Public Health, and directs the Public Health Dynamics Laboratory, a modeling and simulation group at the University. He also holds appointments as professor of Medicine, professor of Industrial Engineering and professor of Clinical and Translational Science. He obtained a bachelor’s degree in Economics from Harvard College, a Doctor of Medicine from Tufts University, and a Master’s in Public Policy from the Kennedy School. He completed training in internal medicine at the Harvard Medical School, where he was a resident and fellow. Over the past 30 years he has conducted several NIH-funded research programs in the use of mathematics, simulation and decision sciences to improve health care decisions and the delivery of care. He was the founding chief of the Section of Decision Sciences and Clinical Systems Modeling, a research section in the department of Medicine.  He has published over 170 papers in academic journals, and been funded on over 40 federally funded grants. He was the 2014 Recipient of the Society for Medical Decision Making Lifetime Achievement Award for contributions in decision sciences. Educationally, he has developed and taught courses in decision analysis and cost effectiveness analysis for several universities, professional societies, pharmaceutical companies and other organizations, both domestically and internationally.  He has been the Chair of the education committee for the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), and is a member of several other national societies, including the recent President of the society for Medical Decision Making. For the federal government, he has been a member of several NIH research grant review panels, and for two years was chair of the Health Care Technology Assessment and Decision Science review panel. 

Elisabeth Fenwick is a Senior Director in the Modeling and Meta-Analysis team based in the UK. Liz provides scientific and strategic support to HE projects globally. She has extensive experience in economic evaluation and health economic modelling having worked in the field for over 20 years. She has worked on a variety of projects in a wide range of disease areas including oncology, respiratory, infectious diseases, cardiology, ophthalmology and orphan diseases. Liz has also contributed to methods in the field, in particular relating to decision analytic modelling and simulation methods, probabilistic decision analytic modelling and value of information analysis. Liz was a member of the ISPOR joint task force on good research practices in modelling and a co-author on the joint taskforce paper on uncertainty and is currently co-chairing the ISPOR task force assessing emerging good practice in value of information analysis for research decisions. Liz is also an Associate Editor for Medical Decision Making and a member of the editorial board for Pharmacoeconomics. Liz has a PhD and MSc in Health Economics as well as an MSc in Operations Research and joined Pharmerit from ICON plc where she lead the modeling team for the global HE group. Prior to her consultancy career, Liz spent over 15 years as an academic working at University of York, McMaster University and most recently University of Glasgow.

Dr. Paul Tappenden is a Reader in Health Economic Modelling within the Health Economics and Decision Science Section at ScHARR. He has over 14 years’ experience in designing, developing, and critically appraising health economic models across many disease areas. Since joining ScHARR in 2000, Paul has been involved in a number of research studies for the National Institute for Health and Care Excellence (NICE), including assessments of therapies for multiple sclerosis, influenza prophylaxis, ulcerative colitis, cystic fibrosis, and colorectal cancer. Paul has a special interest in modelling the cost-effectiveness of technologies for the prevention, detection, treatment, and follow-up of colorectal cancer. Paul has also undertaken modelling assessments for the NIHR Evaluation, Trials and Studies Coordinating Centre (NETSCC), the Advisory Group for National Specialised Services (AGNSS), the Department of Health and NHS Cancer Screening Programmes, including an options appraisal of colorectal cancer screening programmes. Paul is a member of the NICE Decision Support Unit (DSU) and also a member of NICE Technology Appraisal Committee C.

Beth Woods, MSc, is a Research Fellow at the Centre for Health Economics (CHE), University of York. Her research interests include the application of statistical and decision analysis methods to health technology assessment (HTA) and research prioritisation. Prior to joining CHE, Beth was a Director in the Health Economics team at Oxford Outcomes, a private consulting firm, where she specialised in applied economic evaluation from 2006-2013. During this time Beth contributed to numerous submissions to the National Institute for Health and Care Excellence (NICE) and other HTA agencies internationally. Beth holds a BA in Economics from the University of Cambridge and an MSc in Economic Evaluation in Healthcare from City University.

Carrie Bennette is a principal quantitative scientist at Flatiron Health and an affiliate assistant professor at the University of Washington.  She holds a PhD in health economics and outcomes research from the University of Washington, an MPH from Columbia University and has over 100 peer-reviewed publications in health economics and outcomes research.  Carrie's current research focuses on developing and applying statistical methods that leverage real-world data to accelerate clinical research in oncology.  At Flatiron Health, Carrie is focused on building and validating external control arms using real-world data to support regulatory and coverage decisions.

Blythe Adamson is an epidemiologist and economist accelerating the development of valuable medicines and health policy. She serves as Principal Scientist at Flatiron Health in New York. Dr. Adamson advances artificial intelligence applications of natural language processing and machine learning in the curation of electronic health records for real world evidence with a team of engineers, scientists, and clinicians. She designs treatment comparative-effectiveness studies, codes mathematical models of disease, and delivers research for global health technology assessment. Dr. Adamson served as a former member of the White House COVID Task Force on Healthcare Resilience while lead pandemic data scientist in the West Wing. She is an Affiliate Professor at the University of Washington in the Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute. Dr. Adamson has held roles at the Bill and Melinda Gates Foundation Institute for Disease Modeling, Infectious Economics, the NIAID HIV Vaccine Trials Network, and Fred Hutch Cancer Center. She continues to serve as a leader in the International Society for Health Economics and Outcomes Research (ISPOR). Dr. Adamson holds degrees in pharmaceutical economics, public health epidemiology, and microbiology.

As MME’s Global President & CEO, Jack provides critical global support for strategic marketing and pricing decisions to clients in the biotech and pharmaceutical industries. As a recognized expert consultant since 2001, he has successfully completed engagements encompassing many product classes and therapeutic areas and markets, including chronic care, oncology, injectable, and other specialty products all centered on value and its interaction with pricing, payers, reimbursement, and marketing in general at both MME and predecessor organizations. Medical Marketing Economics (MME) is a global leader in the development of value-based strategies and research for health care goods and services. MME’s value-based solutions provide our clients with unique guidance, insights, marketing strategies, and tactics. We identify and address appropriate opportunities, problems, and questions through practical experience, academic rigor, business acumen, and a passion for our work. We help our clients appreciate, understand, and arrive at informed decisions that capture value and thereby succeed. Please visit www.m2econ.com to learn more about our methods and experience.  During his tenure at Roche Laboratories Inc., Jack established that company’s Pharmaceutical Pricing and Contracting Department. As the Director of this group, he successfully increased the size and scope of the group’s activities dramatically to cover a multitude of strategic, tactical, and operational issues involving pricing, reimbursement, and discounting in both the United States and other major global markets. Market segments covered globally, include market access/managed care, biologics, hospital, oncology, government, as well as emerging pricing and reimbursement issues.  Previously, Jack spent ten years as a commercial banker in corporate lending, managing relationships for customers ranging in size from multibillion-dollar organizations to entrepreneurial firms and not-for-profit organizations. He received a BS in Finance from Lehigh University.

Dr. Dellamano – President of MME Europe and founder and President of ValueVector – had been for seven years (from 1996 to 2003) the Head of Strategic Pricing at the global Headquarters of the Swiss pharmaceutical giant Hoffmann-La Roche. In his consultancy activity and during his tenure as global pricing lead at Roche, Dr. Dellamano was instrumental in analyzing and developing global pricing and reimbursement strategies for products in numerous therapeutic areas. A Health Economist and a former Professor of Hospital Management, Dr. Dellamano combines a solid methodological background with extensive global and local business experience in the areas of strategic planning, business development, pharmaceutical pricing and reimbursement, market access, and health economics.

Brett Hauber, PhD, is a Senior Economist and the Vice President of Health Preference Assessment at RTI-HS and an Affiliate Associate Professor in the School of Pharmacy at the University of Washington. He has more than 20 years of academic, research, and government experience in health and environmental economics. He was the principal investigator for developing the Catalog of Methods for Assessing Patient Preferences for Benefits and Harms of Medical Technologies for the Medical Device Innovation Consortium (MDIC). He is currently Co-Chair for Benefit-Risk Assessment in the Benefit-Risk Assessment, Communication, and Evaluation (BRACE) Special Interest Group (SIG) of the International Society for Pharmacoepidemiology (ISPE). He previously served as chair of the Conjoint Analysis Good Research Practices Task Force of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) that developed the report on Good Research Practices in Statistical Methods for the Analysis of Discrete-Choice Experiments and was a member of the ISPOR task force that developed the ISPOR Checklist for Good Research Practices in Conjoint Analysis. Dr. Hauber is currently the Principal Investigator for the What Matters Most Study sponsored by AD PACE, a patient- and caregiver-led collaboration of industry, academics, and government agencies. He was recently the lead investigator an MDIC-sponsored study to elicit patient preferences for benefits and risks of medical devices to treatment Parkinson’s disease. The Parkinson’s preference study was the result of a collaborative effort by MDIC, the Center for Devices and Radiological Health of the Food and Drug Administration (FDA), The Michael J Fox Foundation for Parkinson’s Research, and the Massachusetts Institute of Technology to develop a patient-centered design for clinical trials of devices to treat Parkinson’s disease. Dr. Hauber is currently a member of the Scientific Advisory Board for IMI-PREFER. His research has been published in numerous health outcomes and medical journals.

Deborah Marshall, PhD is a Professor in the Department of Community Health Sciences, University of Calgary, Arthur J.E. Child Chair in Rheumatology Outcomes Research and former Canada Research Chair, Health Services and Systems Research. Her research program focuses on the measurement of preferences, cost-effectiveness analysis, and simulation modeling of health services and interventions. Deborah has over 20 years of research experience in health technology assessment agencies, academic institutions, and industry settings in Canada, US, and Europe. She is a founding co-investigator of the Patient and Community Engagement Research (PaCER) Program at the University of Calgary co-leads the economics and stated preferences research platforms for the Canada-Netherlands Personalized Medicine Network in Childhood Arthritis and Rheumatic Disease (UCAN CANDU). Deborah is an active member of the ISPOR as the past-President of the Board of Directors, and as a member of the Patient Preferences Special Interest Group. She is a co-author on the three ISPOR Task Force Reports for Good Research Practice – Checklist for Conjoint Analysis in Health, Conjoint Analysis Experimental Design and Statistical Methods for the Analysis of Discrete-Choice Experiments. She also chaired the two reports from the ISPOR Dynamic Simulation Modeling Application in Health Care Delivery Research Emerging Good Practices Task Force.

Nasuh Buyukkaramikli is a senior researcher and assistant professor at iMTA/Erasmus School of Health Policy & Management. He has a master degree in Industrial Engineering (IE) from Bilkent University, Turkey (2006) and holds a PhD in Industrial Engineering from Eindhoven University of Technology, The Netherlands (2012). In his dissertation, he analyzed the integrated capacity and resource availability optimization in maintenance service organizations under different capacity flexibility options. He has several years of consulting experience in Health Economics/Outcome Research and also acts as a member of ERG in NICE technology appraisals. He has worked in several medium to big scale private/public funded projects, was the main developer of several (early-stage) decision analytical models used in cost-effectiveness / budget-impact analyses, conducted country adaptations, participated in systematic/targeted reviews, contributed to business development activities and took part in communication development with Key Opinion Leaders (KOLs), medical experts and clients. His main methodological areas of interest are: probabilistic decision analytic modelling, statistical modelling/analysis, value of information analysis, evidence synthesis and operations research.

Praveen Thokala joined the School of Health and Related Research (ScHARR) at the University of Sheffield after completing an MASc from the University of Toronto and a PhD from the University of Southampton. 

During this time, he has completed several health economics projects including single technology appraisals (STA), multiple technology appraisals (MTA), and diagnostic assessment reports (DARs) for NICE. He has also recently led a modeling project for Institute for Clinical and Economic Review (ICER) in the US. His research interests include health economic modeling, multi-criteria decision analysis (MCDA), discrete event simulation modeling, and optimization. He co-supervised four PhD students to completion and currently co-supervises four PhD students. 

In terms of MCDA, he has worked with the National Institute of Health and Care Excellence  decision support unit (NICE DSU) in the UK on exploring the applicability of MCDA in HTA. He co-chaired the ISPOR Task Force on the use of MCDA in healthcare decision making and has been involved in several MCDA studies including supporting priority setting and benefit-risk analysis. He also co-edited a book titled, Multi-Criteria Decision Analysis to Support Healthcare Decisions. 

Alec Morton has degrees from the University of Manchester and the University of Strathclyde. He has worked for Singapore Airlines, the National University of Singapore, and the London School of Economics, has held visiting positions at Carnegie Mellon University in Pittsburgh, Aalto University in Helsinki, the University of Science and Technology of China (USTC) in Hefei, and the National Audit Office and is a member of the International Decision Support Initiative. His main interests are in decision analysis and health economics.  His research is funded by the European Commission, the Department of Health, the Medical Research Council and Engineering and Physical Sciences Research Council, and the Chief Scientist's Office of the Scottish NHS. Alec has been active in the INFORMS Decision Analysis Society, EURO and ISPOR. He is on the Editorial Board of Decision Analysis and is an Associate Editor for the EURO Journal on Decision Processes, the Transactions of the Institute of Industrial Engineers, and OR Spectrum. Past consulting clients include the National Audit Office, the Department of Health, the Environment Agency, the Nuclear Decommissioning Authority and the Global Fund to Fight AIDS, Tuberculosis & Malaria. His papers have won awards from the International Society for Pharmacoeconomics and Outcomes Research and the Society for Risk Analysis.  His book Portfolio Decision Analysis with Jeff Keisler and Ahti Salo won the INFORMS Decision Analysis Society publication award in 2013 and his paper "CUT: A Multicriteria Approach for Concavifiable Preferences" (with Nikos Argyris and Jose Figueira) was a finalist for the same prize in 2016 .

Jon Tosh, PhD, is a Research Scientist in Modelling and Simulation at Evidera with over 10 years of experience. He has extensive experience of economic modelling, operations research, simulation modelling, cost-effectiveness analysis and HTA. He is experienced at applying advanced mathematical modelling solutions to a range of problem types. Jon is a member of the editorial board for Pharmacoeconomics Open. Prior to joining Evidera, Jon spent 2.5 years at DRG Abacus as a consultant health economist working on global health economics research. Before this, Jon spent over 8 years working as a health economist at the University of Sheffield. His role spanned teaching, research, and methodology. Jon has in depth knowledge of NICE, and was formally a member of the University of Sheffield Technology Assessment Group and the NICE Decision Support Unit. He has developed cutting-edge health economic methods and has published over 20 peer-reviewed journal publications. Jon was awarded his PhD in Health Economics from the University of Sheffield in 2015. His PhD spanned operations research, health economics, simulation modelling and optimisation. He also has an MSc in Health Economics from the London School of Economics, and a BA(Hons) in Economics from the University of Leicester. His experience covers a wide range of therapeutic areas including immunology, oncology, hepatology, neurology, mental health, cardio-vascular disease, and ultra-orphan conditions. Jon is currently a member of the emerging good practices ISPOR task force on constrained optimization methods in health care delivery. He has been a podium, workshop and forum presenter and short course instructor at previous ISPOR meetings.

Uwe Siebert, MD, MPH, MSc, ScD, is a professor of Public Health, Medical Decision Making and Health Technology Assessment (HTA), chair of the Department of Public Health, Health Services Research and HTA at UMIT TIROL-University for Health Sciences and Technology in Austria and director of the Division for HTA in the ONCOTYROL–Center for Personalized Cancer Medicine in Austria. He is also adjunct professor of Epidemiology and Health Policy & Management at the Harvard T.H. Chan School of Public Health and Affiliated Researcher in the Program on Cardiovascular Research at the Institute for Technology Assessment and Department of Radiology at the Massachusetts General Hospital, Harvard Medical School, Boston.

After medical school, he worked for several years as a physician in international public health projects in West Africa, Brazil, and Germany. He then earned an MPH at the Munich School of Public Health and completed an MSc in Epidemiology and a ScD in Health Policy and Management with a concentration in decision sciences at the Harvard School of Public Health.

His research interests include applying real-world evidence-based quantitative, causal and translational methods from public health, epidemiology, artificial intelligence, comparative effectiveness research, health services and outcomes research, economic evaluation, modeling, and health data a d decision science in the framework of health care policy advice and HTA as well as in the clinical context of routine health care, clinical guideline development, public health policies and patient guidance. His research focuses on cancer, infectious disease, cardiovascular disease, neurological disorders, and others.

He has been leading projects/work packages in several EU FP7, H2020 and Horizon Europe projects (eg, ELSA-GEN, BiomarCaRE, MedTecHTA, DEXHELPP, EUthyroid, FORECEE, MDS-RIGHT, RECETAS, CORE-MD, EUREGIO-EFH, CIDS, OnCoVID, 4D PICTURE, CATALYSE). He teaches HTA, health economics, modeling, epidemiology, causal inference and target trial emulation, and data and decision science for academia, industry, and health authorities in Europe, North and South America, and Asia. He directs the Continuing Education Program on Health Technology Assessment & Decision Sciences (htads.org).

He has served as member of the ISPOR Directors Board and as president of the Society for Medical Decision Making (SMDM). He is a leadership member of the ISPOR Personalized/Precision Medicine SIG, a member of the Latin America Consortium Advisory Committee of ISPOR, and co-chair of the ISPOR-SMDM Modeling Good Research Practices Task Force. He is a member of the Oncology Advisory Council and the National Committee for Cancer Screening of the Austrian Federal Ministry of Health.

He has authored more than 400 publications (> 30,000 citations, H index > 80), and is editor of the European Journal of Epidemiology. Further information Internet: http://htads.org, umit-tirol.at/dph, hsph.harvard.edu/uwe-siebert, Twitter: @UweSiebert9, LinkedIn: uwe-siebert9.

Uwe Siebert, MD, MPH, MSc, ScD, is a professor of Public Health, Medical Decision Making and Health Technology Assessment (HTA), chair of the Department of Public Health, Health Services Research and HTA at UMIT TIROL-University for Health Sciences and Technology in Austria and director of the Division for HTA in the ONCOTYROL–Center for Personalized Cancer Medicine in Austria. He is also adjunct professor of Epidemiology and Health Policy & Management at the Harvard T.H. Chan School of Public Health and Affiliated Researcher in the Program on Cardiovascular Research at the Institute for Technology Assessment and Department of Radiology at the Massachusetts General Hospital, Harvard Medical School, Boston.

After medical school, he worked for several years as a physician in international public health projects in West Africa, Brazil, and Germany. He then earned an MPH at the Munich School of Public Health and completed an MSc in Epidemiology and a ScD in Health Policy and Management with a concentration in decision sciences at the Harvard School of Public Health.

His research interests include applying real-world evidence-based quantitative, causal and translational methods from public health, epidemiology, artificial intelligence, comparative effectiveness research, health services and outcomes research, economic evaluation, modeling, and health data a d decision science in the framework of health care policy advice and HTA as well as in the clinical context of routine health care, clinical guideline development, public health policies and patient guidance. His research focuses on cancer, infectious disease, cardiovascular disease, neurological disorders, and others.

He has been leading projects/work packages in several EU FP7, H2020 and Horizon Europe projects (eg, ELSA-GEN, BiomarCaRE, MedTecHTA, DEXHELPP, EUthyroid, FORECEE, MDS-RIGHT, RECETAS, CORE-MD, EUREGIO-EFH, CIDS, OnCoVID, 4D PICTURE, CATALYSE). He teaches HTA, health economics, modeling, epidemiology, causal inference and target trial emulation, and data and decision science for academia, industry, and health authorities in Europe, North and South America, and Asia. He directs the Continuing Education Program on Health Technology Assessment & Decision Sciences (htads.org).

He has served as member of the ISPOR Directors Board and as president of the Society for Medical Decision Making (SMDM). He is a leadership member of the ISPOR Personalized/Precision Medicine SIG, a member of the Latin America Consortium Advisory Committee of ISPOR, and co-chair of the ISPOR-SMDM Modeling Good Research Practices Task Force. He is a member of the Oncology Advisory Council and the National Committee for Cancer Screening of the Austrian Federal Ministry of Health.

He has authored more than 400 publications (> 30,000 citations, H index > 80), and is editor of the European Journal of Epidemiology. Further information Internet: http://htads.org, umit-tirol.at/dph, hsph.harvard.edu/uwe-siebert, Twitter: @UweSiebert9, LinkedIn: uwe-siebert9.

Olivia Wu, PhD, is the Deputy Director of the HEHTA Research Unit at the University of Glasgow, where she also leads the Evidence Synthesis Research Programme. She has a BSc (Hons) in Pharmacy, MSc in Clinical Pharmacology and PhD in Public Health and Health Economics. Olivia’s research interest in health technology assessment methodologies focuses on the areas of evidence synthesis (including systematic review and meta-analysis of aggregate and individual patient data; direct, indirect and networked evidence), risk prediction modelling and economic evaluation. She has undertaken research in a variety of clinical areas including cardiovascular disease, hematology, obstetrics and gynecology, and rheumatology. In addition to her research, Olivia serves as a member of Technology Appraisal Committee for the National Institute for Health and Care Excellence (NICE) and the Health Service and Population Health Research Committee for the Chief Scientist Office (CSO) Scotland. She is also the Health Economics Advisor to the Scottish Intercollegiate Guidelines Network (SIGN).

Dr. Neil Hawkins is a Professor of Health Technology Assessment (HTA) at the University of Glasgow.  He was previously Vice President leading the global Health Economics practice at ICON PLC following its acquisition of Oxford Outcomes Ltd, where he served as a Member of the Board of Directors. Over the previous fifteen years, Neil has participated in methodological and applied research regarding the relative and cost-effectiveness of health technologies. In addition to participating individual evaluations, he has published articles discussing methods for network meta-analysis, cost-effectiveness modeling, value based pricing and the placebo effect. More recently, he has focused on the application of HTA “thinking” during the process of technology development and the development of conceptual models of value. He received Master’s Degrees in Health Economics (York) and Applied Statistics (Sheffield Hallam) and a BSc and PhD in Pharmacology (University of Bristol) and an MBA (University of Oxford).  He is also a Chartered Statistician with the Royal Statistical Society, UK. For more details please see: https://neilhawkins.wordpress.com/

Jim Lewsey, PhD, is a Reader in Medical Statistics and joined the University of Glasgow in 2007 having previously held posts at the London School of Hygiene and Tropical Medicine (2003-2007), University of Otago (2001-2003), Eastman Dental Institute-UCL (1998-2001), and University of Glasgow (1996-1998). He was awarded Chartered Statistician status from the Royal Statistical Society in 2010 and Chartered Scientist from the Science Council in 2012. His personal research interests stem from methodological challenges faced when analyzing observational and experimental medical data and have included prognostic model development in the presence of missing data, continuous outcome monitoring of long-term outcomes, modelling dental caries data, and design of cluster randomised trials. His current methodological interests include multi-state survival analysis and modelling of data from natural experiments, and in his applied research he is developing a portfolio of alcohol research. Jim leads the Analysis of Linked Health Data (ALDA) programme within HEHTA and is Deputy Lead of the IHW research theme 'Data Science - Using routine administrative data and record linkage for research'. Jim is Programme Director and teaches on the MSc in Health Technology Assessment.  He also teaches and coordinates a medical statistics course on the Masters in Public Health.

Gerd Rosenkranz, PhD, studied Mathematics and Physics at the University of Heidelberg (Germany) and worked as a Biostatistician with the German Cancer Research Center. After having received his PhD, he was with the pharmaceutical industry for almost 30 years covering preclinical and clinical development of new therapies, mainly with Hoechst (now Sanofi-Aventis) in Frankfurt, Germany and Sandoz/Novartis in Basel, Switzerland. During his 20+ years in Novartis he led the Statistics Oncology Group, later joined the Statistical Methodology Group and became Scientific Officer Biostatistics. In the this role he was representing the statistics function in the review of clinical studies and development plans of Novartis Pharmaceuticals in cardiovascular, immunology, respiratory, neurology, among others. Since beginning of 2016 Gerd is a Visiting Professor with the Statistics Group of the Medical University of Vienna. His main professional interests are design and analysis of clinical trials, in particular missing data, subgroups, and quantitative decision making in clinical projects. He is co-Editor of Pharmaceutical Statistics.

Dr. John Seeger is a pharmacoepidemiologist and Chief Scientific Officer at Optum Epidemiology. He is also Adjunct Assistant Professor in Epidemiology at the Harvard School of Public Health. Dr. Seeger has conducted dozens of studies that have addressed regulatory drug safety issues across a wide range of drugs and disease conditions. Most of this work has involved the use of health insurance claims databases as platforms for pharmacoepidemiology, so Dr. Seeger's methodological expertise focuses on research issues encountered in such settings. He has worked extensively with propensity scores and related methods that mitigate confounding by collapsing covariates. Additionally, he is a co-Instructor in courses on propensity scores and is the past President of the International Society for Pharmacoepidemiology (ISPE).

Jeremy A. Rassen, MS, ScD is co-founder, president, and chief science officer at Aetion, a health care technology company that delivers real-world evidence for life sciences companies, payers, and regulatory agencies. 

Prior to founding Aetion, Dr. Rassen was assistant professor of Medicine at Harvard Medical School, where he focused on methods to improve the quality and validity of real-world data studies. Dr. Rassen frequently speaks and publishes in peer-reviewed publications on how real-world data can be used to measure the safety, effectiveness, and value of medications and other treatments.  

Before coming to Harvard, Dr. Rassen worked in Silicon Valley at a variety technology companies, including Hewlett-Packard and Epiphany, Inc.  His focus was on high-performance software for the creation and analysis of large databases.  

Dr. Rassen received his bachelor’s degree in Computer Science from Harvard College and his masters and doctorate degrees in Epidemiology from the Harvard T.H. Chan School of Public Health.  

Sorrel Wolowacz, PhD, is Head of European Health Economics at RTI HS with 15 years of experience in heath economics consulting and 25 years of experience in the health care industry, including health outcomes, clinical research, and product development. She has research experience in the areas of economic modeling, analysis of health utility and resource use data (collected alongside trials, by medical record abstraction, surveys, or within databases), formal health technology appraisal submissions, systematic reviews, and compilation of value dossiers. Dr. Wolowacz also has experience in various therapeutic areas, including oncology (specifically lung, breast, ovarian, skin, and hematological cancers), cardiology, respiratory, venous thromboembolism, arthritis, chronic pain, ophthalmology, and dermatology. She has participated in health technology appraisals in several countries, including the United Kingdom (National Institute for Health and Care Excellence and Scottish Medicines Consortium), Ireland (National Centre for Pharmacoeconomics), Australia (Pharmaceutical Benefits Advisory Committee), and Canada (Canadian Agency for Drug and Technologies in Health, Canadian Drug Review). Dr. Wolowacz is a member of the Editorial Board for the Journal of Comparative Effectiveness Research and acts as Peer Reviewer for Pharmacoeconomics, European Journal of Health Economics, American Journal of Clinical Oncology, Value in Health, and Therapeutics and Clinical Risk Management. She was co-Chair of the ISPOR Good Research Practices Task Force addressing Measurement of Health State Utility Estimates for Economic Models in Clinical Studies and is a founding member of the ISPOR Working Group for Oncology Health Economic Modeling.

Andrew Lloyd is the Director of Acaster Lloyd Consulting Ltd, an outcomes research consultancy. Andrew has previously been the VP and Practice Lead at ICON PLC for 4 years, and a Director at Oxford Outcomes and United BioSource Corporation. Prior to 2001 Andrew had academic positions in Leicester, Oxford, and Aberdeen. His main research interests are in the assessment of patient-reported outcomes.  Andrew’s work is concerned with assessing HRQL and patient preferences to support economic submissions for reimbursement to bodies like NICE. Andrew sits on the Executive Committee of the EuroQol group. He undertakes teaching at ISPOR and the University of York.  He is a co-Editor at Value in Health. Andrew has undertaken work in a broad range of therapeutic areas including oncology, diabetes, asthma, and vascular disease. These projects have included assessments of quality of life; utility estimation; determination of patient preferences through discrete choice experiments; and development and validation of novel patient reported outcomes. He completed his DPhil in the Psychology Department at the University of York in 1997. Andrew has published over 85 peer reviewed articles in journals including: Medical Decision Making, Lancet, Value in Health, British Journal of Cancer and others. He has been keynote speaker at national and international conferences. He was the research co-Chair at the ISPOR European Conference in 2009. Andrew has supervised PhD students in the UK and US.

Lynda Doward, MRes, is the European Head of Patient-Centered Outcomes Assessment (PCOA) at RTI-HS. Ms. Doward has over 30 years of experience in PCOA research. She provides advice and guidance to pharmaceutical companies, medical personnel, and academic researchers on the incorporation of PCOA and health-utility measurement into pharmaceutical product development strategies, clinical trial design and questionnaire development, translation, adaptation, and validation. Ms. Doward has particular expertise in research design and in the application of both traditional and innovative qualitative and quantitative research methods. She has extensive experience managing large-scale international projects involving a broad range of therapeutic areas. Ms. Doward was a Lead Member of an International Benefit Assessment Taskforce for Outcome Measurement in Multiple Sclerosis from 2004 to 2009, has acted as a consultant to the World Health Organization and has served as a Research Advisor to the UK Department of Health, and the Arthritis Research Campaign. Ms. Doward has published widely in peer-reviewed journals, has presented her research at numerous international symposia, and acts as Peer Reviewer for Value in Health, Pharmacoeconomics, Quality of Life Research, and several other journals.

Shelby is a Director of Health Economics and Outcomes Research (HEOR) with Pharmerit International, a global HEOR consultancy based in Bethesda, MD. She received her PharmD degree from the University of Pittsburgh School of Pharmacy in 2002, after which she completed a specialty residency in Drug Information at the University of Pittsburgh Drug Information Center in conjunction with the University of Pittsburgh Medical Center (UPMC). After completing this training, Shelby joined the faculty at the University of Pittsburgh and worked in formulary management and drug policy at UPMC, while conducting outcomes research in a variety of therapeutic areas. In 2011, Shelby completed a Master of Science degree in Clinical Research (Health Services Research Track) at the University of Pittsburgh School of Medicine, with thesis work focusing on the cost-effectiveness of new medications in comparison to older, standard-of-care therapies. In 2012, Shelby joined Pharmerit International as a scientist specializing in economic modeling, real-world evidence, and strategic market access. Since joining Pharmerit, Shelby has conducted numerous health economic evaluations, medical chart review studies, claims database analyses, and reimbursement dossiers as a consultant to the pharmaceutical, biotechnology, and medical device industries. Her therapeutic areas of expertise include postsurgical pain, infectious diseases, oncology, and solid organ transplant.

Mark S. Roberts, MD, MPP is Professor and Chair of the Department of Health Policy and Management at the University of Pittsburgh Graduate School of Public Health, and directs the Public Health Dynamics Laboratory, a modeling and simulation group at the University. He also holds appointments as professor of Medicine, professor of Industrial Engineering and professor of Clinical and Translational Science. He obtained a bachelor’s degree in Economics from Harvard College, a Doctor of Medicine from Tufts University, and a Master’s in Public Policy from the Kennedy School. He completed training in internal medicine at the Harvard Medical School, where he was a resident and fellow. Over the past 30 years he has conducted several NIH-funded research programs in the use of mathematics, simulation and decision sciences to improve health care decisions and the delivery of care. He was the founding chief of the Section of Decision Sciences and Clinical Systems Modeling, a research section in the department of Medicine.  He has published over 170 papers in academic journals, and been funded on over 40 federally funded grants. He was the 2014 Recipient of the Society for Medical Decision Making Lifetime Achievement Award for contributions in decision sciences. Educationally, he has developed and taught courses in decision analysis and cost effectiveness analysis for several universities, professional societies, pharmaceutical companies and other organizations, both domestically and internationally.  He has been the Chair of the education committee for the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), and is a member of several other national societies, including the recent President of the society for Medical Decision Making. For the federal government, he has been a member of several NIH research grant review panels, and for two years was chair of the Health Care Technology Assessment and Decision Science review panel. 

Kirk Geale works as a Senior Project Leader at Quantify Research, with more than six years’ experience in health economics and outcomes research (HEOR) consultancy. Kirk holds a Bachelor of Commerce in Management Economics in Industry and Finance from Guelph University (Canada), an MSc in Economics from Lund University (Sweden), and is currently a PhD candidate in Medicine at Umeå University (Sweden). His expertise revolves around health economic modelling and observational data analysis, and the interactions between them. Kirk is interested in the analysis of longitudinal data and the associated methodology, using these to improve the validity of economic and medical research to benefit patients and society. His work spans several therapy areas including immunology, dermatology, gynecology, multiple sclerosis, musculoskeletal, and respiratory. He is active in both industry and academia.

Dr Anders Gustavsson is co-founding partner at Quantify, and holds an MSc from the Stockholm School of Economics and a PhD in Health Economics from Karolinska Institutet, Sweden. During his PhD studies, Anders developed new methods for the economic evaluation of treatment for Alzheimer’s disease. Anders has worked with health economics since 2005, first as researcher at European Health Economics and from 2008 as Associate Director at i3 Innovus, leading a research team in neuroscience. In 2011, he co-founded Quantify Research, a consultancy in health economics, outcomes research and real world evidence. As a consultant, Anders has worked with pharma and biotech companies, patient organisations, health care providers and government institutions. He has a broad competence within research and has co-authored over 30 peer-reviewed papers including registry studies, prospective cohorts, within-trial analysis, patient- and caregiver preference studies and decision analytic models. Anders was coordinator and first author of the European study on the costs of brain disorders (2010), initiated by European Brain Council. He is affiliated to Karolinska Institutet and a co-organiser of the International Pharmaco-Economic Conference on Alzheimer’s disease (IPECAD).

Kevin Marsh, PhD, is Executive Director at Evidera in London, UK. He specializes in the use of preference data and decision analysis to inform health decisions, including pipeline optimisation, authorisation, reimbursement, and prescription decisions. Dr Marsh’s research interests include stated and revealed preference methods, decision modelling, and MCDA. He has applied these and other research techniques for a range of organisations, including both regulatory and industry clients. He actively contributes to the methodological development of these techniques. He is currently co-Chairing the ISPOR Task Force on the Use of MCDA in Health Care Decision-Making, and is a co-Convenor of the Campbell and Cochrane Economic Methods Group. Dr Marsh completed his PhD at the University of Bath, specialising in economic valuation techniques. After a year at Oxford University, he joined the Matrix Knowledge Group in London, before joining Evidera in April 2012.

Maarten J. IJzerman is a VCCC professor and head of Cancer Health Services Research in the Faculty of Medicine, Dentristry and Health Sciences of the University of Melbourne in Australia. He also holds a fractional appointment as a professor of Health Technology Assessment in the University of Twente, where he was the Vice-Dean in the Faculty of Science.  Maarten is an active global researcher with multiple research visits and collaborations in the USA, UK and Canada. He is an active ISPOR member, serves in different ISPOR taskforces and committees, and promotes active collaboration between ISPOR and the European Cancer Organisation (ECCO). In 2016, he joined the European Society for Medical Oncology (ESMO) Cancer Medicines working group dealing with the disparities in access to cancer drugs. Maarten is a member of the board of two hospitals in the Netherlands, responsible for quality and safety and strategy/innovation.

Baudouin “Bo” Standaert was born in Bruges, Belgium. He studied medicine (MD) at the KU Leuven and Tropical Medicine in Antwerp (1982). During the first 7 years of his career Bo had a mixed work assignment in academia (University of Antwerp and UCL in Brussels) and abroad (Suriname, Burundi, Salomon islands, WHO (Geneva)). In 1988 he became director of the Provincial Institute of Hygiene in Antwerp. The Institute had around 160 employees split into lab and field work in collecting basic health and environmental information. During that period Bo was the representative of Belgium in the scientific board of IARC in Lyon, France for 4 years. His interest in economic evaluations of health care emerged with the collaboration with the University of Antwerp in 1990. At that time different pharmaceutical companies were interested in getting HE-expertise in house. Bo took the decision in 1995 to join AMGEN to become their first health economist in Europe. A small team of 8 people was set up in Brussels coordinating all their HE-activities. In 2005, it was time to move to another international group in Belgium and to start working on vaccines. Bo became the head of the global HE-team of vaccines in GSK, Wavre, Belgium. He started with 3 collaborators, first working on Rotarix and Cervarix and later on Synflorix. The group counts now 12 persons. The HE-team has a wide experience in developing different types of economic assessments from simple back-of-the envelope models to more advanced dynamic and macro-economic models for pandemic infectious diseases such as malaria, TB, HIV, Flu. The HE-team explores new economic value evidence (Quality of Care, absenteeism, herd effect) away from the conventional cost-effectiveness analysis including optimisation modelling, return on investment, and fiscal modelling. Bo has numerous publications in the many different fields he worked on. He obtained his PhD on rotavirus vaccination, exploring new ways of economic assessment, at the University of Groningen, the Netherlands, in 2015. He was the industrial representative of the WHO-IVIR-working group for 9 years. He co-chaired the taskforce on economic evaluation of vaccines for ISPOR (2016-2018) and was recently appointed industrial lead for the European IMI-Vital (2018-2022) project on vaccination in elderly.

Mark Connolly is health economist with over 19 years of experience gained in the pharmaceutical industry, consulting and academia. He has a wide range of pharmaceutical market access, economic modeling and cost-effectiveness experience supporting new product launches and lifecycle management while working in global and regional roles within the pharma industry. His research interests include the economics of healthcare and understanding the broader public economic impact of investments in healthcare applying government perspective frameworks. Dr. Connolly is also the Managing Director and Founder of Global Market Access Solutions with licensed offices in Switzerland, UK and United States. He also holds a guest research position at the University of Groningen Pharmacoeconomics and Pharmacoepidemiology Unit in the Netherlands.

Health economist with 16 years of experience in the pharmaceutical industry and consulting. Extensive pharmaceutical reimbursement and health economic experience gained working in Europe and international markets, having held global and regional positions for the pharmaceutical industry and as strategy consultant. Produced diversified health economic analyses for developed and developing countries with over 30 peer-reviewed articles and abstracts published. His research focuses on the development and implementation of novel analytic frameworks that assess the public economic effects of healthcare investments.

Oleksandr is a health economist with 10 years of experience within pharmaceutical industry, consulting and government positions. He is a founder of Digital Health Outcomes, company providing specialised digital solutions for HEOR, Clinical and Regulatory domains. He is also a member of the National EML Committee, an advisor to the MoH and a World Bank consultant working on the healthcare reform in Ukraine. Following his MSc in financial economics from Kiev Schevchenko University, he also obtained a Health Economics PGDip degree from the University of York, UK.

Christopher S. Hollenbeak, PhD is Professor and Head of the Department of Health Policy and Administration at the Pennsylvania State University. Dr. Hollenbeak has broad interests in health economics and health outcomes research, with a particular focus on economic issues in surgery. In previous research he has studied modifications to the kidney allocation mechanism, estimated the cost-effectiveness of screening for head and neck cancer, and estimated the burden of surgical site infections after major abdominal and cardiothoracic surgical procedures. Dr. Hollenbeak received his doctorate in Economics from Washington University in St. Louis, where he studied Bayesian econometrics under Ed Greenberg and Siddhartha Chib. He uses Bayesian methods in meta-analysis and to fit nonlinear risk adjustment models for continuous hospital performance measures.

Keith Abrams, PhD, is a Professor of Medical Statistics in the Department of Health Sciences at the University of Leicester, having previously held appointments at the London School of Hygiene and Tropical Medicine and King’s College School of Medicine and Dentistry, London, UK. He is a Fellow of the Royal Statistical Society, and a Chartered Statistician. His research interests are primarily concerned with the development and application of Bayesian statistical methods in Health Technology Assessment (HTA), in particular their application to clinical trials, evidence synthesis, and decision modelling, and Non-Communicable Disease (NCD) epidemiology. This work is primarily supported with funding from EU, Medical Research Council (MRC), National Institute for Health Research (NIHR) and industry. Professor Abrams has been extensively involved with the UK NIHR Health HTA Programme and UK National Institute for Health & Care Excellence (NICE) appraisal process since their inception. He was a member of the NICE Technology Appraisals Committee for over 8 years until 2015, is a member of the NICE Decision Support Unit and Technical Support Unit, and a NIHR Senior Investigator Emeritus.  He has published widely in both substantive and methodological areas including co-Authoring books on Methods for Meta-Analysis in Medical Research, Bayesian Approaches to Clinical Trials and Healthcare Evaluation, and Evidence Synthesis for Decision Making in Healthcare, in addition to co-Editing one of the first texts on Methods for Evidence-based Healthcare.

Dr Ramsey is a general internist and health economist. He is a Professor in the Cancer Prevention Program, Public Health Sciences Division at the Fred Hutchinson Cancer Research Center, where he directs Hutchinson Institute for Cancer Outcomes Research, a multidisciplinary team devoted to clinical and economic evaluations of new and existing cancer prevention, screening and treatment technologies. In addition, Dr. Ramsey is a Professor in the Schools of Medicine and Pharmacy at the University of Washington. 

Trained in Medicine and economics, Dr Ramsey’s research focuses on economic evaluations in cancer. He has published widely on patterns of care, costs, and cost-effectiveness of treatments for lung, colorectal, and prostate cancer.  His research portfolio and interests include: large scale SEER-Medicare/Cancer Registry data linkages, patient reported outcomes, economic modeling of health care interventions, cost-effectiveness analysis, quality of life assessment, patterns of care, health care utilization, economic burden of disease for patients and society, pragmatic trial design, early technology assessment, and stakeholder engagement.

Dr Ramsey is co-Chair National Cancer Institute’s Cancer Care Delivery Research Steering Committee and an executive office for SWOG. He is past President of the International Society of Pharmacoeconomics and Outcomes Research (ISPOR) and has served on the National Academy of Science’s Cancer Policy Forum.

Richard J. Willke, PhD is chief science officer of ISPOR, the leading global professional society for health economics and outcomes research. Dr Willke has more than 25 years of experience in the life sciences arena and has specialized in outcomes research in a succession of group leadership roles with Pfizer and its legacy companies.

At ISPOR, Dr Willke is responsible for designing and implementing strategic initiatives related to scientific research and content priorities that will advance the Society’s mission of promoting health economics and outcomes research excellence to improve decision making for health globally.

Previously, Dr Willke was vice president, Outcomes and Evidence Cluster Lead at Pfizer for its Global Health and Value division. He has also served in a number of leadership roles with affiliated organizations, including the Chair of ISPOR Institutional Council (2010), ISPOR Board of Directors (2007-2009), and Chair of the PhRMA Health Outcomes Committee (2002-2004).

Prior to joining industry, Dr Willke served as department director in the Center of Health Policy Research at the American Medical Association and held research and teaching positions at The Ohio State University.

Dr Willke earned a PhD and MA in economics from Johns Hopkins University. He has authored more than 80 scholarly publications that examine the science and methodologies of health economics and outcomes research.

Sean D. Sullivan, BScPharm, MSc, PhD, is Professor and Dean, School of Pharmacy. He holds a joint appointment as Professor of Health Services in the School of Public Health.  He holds adjunct appointments in the School of Medicine, the Public Health Sciences Division at the Fred Hutchinson Cancer Research Center, and at the Kaiser Permanente Washington Health Research Institute. He completed training in pharmacy at Oregon State University in 1983, obtained a master’s degree at the University of Texas in 1986 and a PhD in health economics and policy at the University of California, Berkeley in 1992. Dr. Sullivan has authored more than 400 journal articles, book chapters, task force reports and organizational and governmental publications. In many of these writings, he has assessed the evidence and applications of medical technology in relation to coverage and reimbursement decisions. His research interests include technology assessment, medical decision-making, and economic evaluation of medical technology. He is past president of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) and past chair of the Academy of Managed Care Pharmacy (AMCP) Executive Committee of the Format for Formulary Submissions – the United States evidence-based guidelines for formulary decision making. Dr. Sullivan served as a past member of the Medicare Evidence Development and Coverage Advisory Committee, a past member of the Regence Blue Shield and Premera Blue Cross P/T Committee, and the Chair of the Premera Blue Cross Value Assessment Committee. He is also on the editorial boards of Value in Health, PharmacoEconomics, Journal of Medical Economics, and the European Journal of Health Economics. He was awarded the 2014 Stephen G. Avey Lifetime Achievement Award from the Academy of Managed Care Pharmacy (AMCP) and the 2015 APhA Academy of Pharmaceutical Research Sciences (APRS) Research Achievement Award.